GLP‑1 medications such as Ozempic, Wegovy and Zepbound are becoming common treatments for diabetes and obesity. They are designed as ongoing therapy for chronic conditions, yet many people who begin these drugs discontinue them within months. Insurance‑claims research led by Dr. Jaime Almandoz at UT Southwestern found that fewer than one in four patients were still taking a GLP‑1 after a year.
People stop for many reasons: some mistakenly believe obesity treatment should end once a weight target is reached, others face cost or a loss of insurance coverage, and some discontinue because of side effects. Still, surveys show most who lapse intend to restart. Market‑research firm Kantar reported that 74% of lapsed users said they were likely or very likely to go back on a GLP‑1. That intention is reinforced as more GLP‑1s appear in pill form, become less expensive, or are sold online in ways that can bypass usual medical oversight.
Clinical evidence about intermittent or cyclical GLP‑1 use is limited. A number of studies suggest weight returns more quickly after stopping GLP‑1s than after behavioral weight‑loss programs. Social and cultural forces—celebrity examples and social‑media marketing that frame these drugs as suitable for short‑term or cosmetic use—also encourage on‑again, off‑again patterns. Some advertisements explicitly normalize brief courses, and debates continue among regulators and industry groups about access and appropriate oversight.
Experts express concern about the effects of repeated, temporary use on body composition. Research indicates a substantial portion of weight lost on GLP‑1s—sometimes as much as around 40%—can be lean muscle rather than fat. Mahmoud Salama Ahmed, a medical chemist at Texas Tech, warns that this muscle loss can be pronounced and may contribute to a gaunter facial appearance sometimes called “Ozempic face.” When people stop the drugs and regain weight rapidly, fat mass often returns faster than muscle. If lost lean mass is not rebuilt, there is concern about sarcopenia, which can impair balance, mobility, metabolism and bone health—risks that are particularly relevant for older adults.
Other researchers urge a more nuanced interpretation. Some analyses suggest GLP‑1 therapy may improve muscle quality—reducing fat infiltration in muscle and supporting healthier muscle fibers—even when overall muscle quantity declines. Cardiologist Ian Neeland at Case Western Reserve emphasizes that muscle function and strength matter as much as mass for health outcomes. Both Neeland and Ahmed agree that more research is needed to clarify how short‑term, intermittent and repeated GLP‑1 use affect muscle, fat distribution and long‑term health.
In short, although many people stop and later plan to restart GLP‑1 medications, these drugs are intended for chronic management of obesity and diabetes. The health consequences of cycling them—especially for body composition and for older adults—are not yet well understood, and more study is needed to guide safe use and policy decisions.